OctoPlus Wins Drug Development and Manufacturing Contract from Danish Pharmaceutical Company
News Jul 06, 2011
OctoPlus N.V. has announced that a process development and manufacturing contract has been signed with a pharmaceutical company headquartered in Denmark.
The undisclosed contract value will make a material contribution to OctoPlus' annual revenues.
Under the contract terms, we will perform process development and manufacturing of a microsphere-based formulation for our client.
At OctoPlus we provide formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide.
In addition to our expertise in formulation and manufacturing, we offer our clients drug delivery technologies for the development of controlled release versions of existing or new drugs.
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE